author-photo

James K. McCloskey

Hackensack University Medical Center

13

Papers

93

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (14)
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (30)
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

2019 Blood
Show All
- Source
- Cite
- Save
Citations (36)
One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Blinatumumab Induces Responses in Extramedulary B-Cell Acute Lymphoid Leukemia (B-ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia (CML), and Rarely Results in CD19 Negative Relapse

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

2017 Blood
Show All
- Source
- Cite
- Save
Citations (6)